- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03981185
aTBS for Treatment of Depression in AUD
Accelerated Theta Burst Stimulation for Treatment of Depression in Individuals With Detoxed Alcohol Use Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Romina Nejad, MSc
- Phone Number: 650-497-3933
- Email: rnejad@stanford.edu
Study Contact Backup
- Name: Huiqiong Deng, MD, PhD
- Phone Number: 650-498-7430
- Email: hdeng397@stanford.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Participant aged 18-65 years old with diagnosis of alcohol use disorder.
- Participant may also choose to or not to take pharmacotherapy during the study period.
- Participant has tried at least one medication in the past that has not helped the alcohol use disorder. If participants are taking medication, they must be on stable psychotropic medication or psychotherapy for at least 6 weeks prior to the study with plans to continue throughout study enrollment.
- Participant needs to be at least one week after last alcohol/ substance use and had the last drink within one year of the beginning of the study participation.
- Participant endorses depressive symptom(s), indicated by a MARDS score >= 20.
- All participants must be assigned to a psychiatrist and agree to continue to be assigned to a psychiatrist throughout study enrollment.
- Able to read, understand, and provide written, dated informed consent prior to screening. Participants will be deemed likely to comply with study protocol and communicate with study personnel about adverse events and other clinically important information.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Accelerated theta burst treatment
All participants will receive theta-burst TMS.
|
All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance. Stimulation will be delivered to L-DLPFC using the MagPRo stimulator. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline Montgomery Asberg Depression Rating Scale (MADRS)
Time Frame: Baseline and immediate post-stimulation
|
A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. The MADRS uses a 0 to 6 severity scale, scored following the interview. Scoring/Interpretation: Higher scores indicate increasing depressive symptoms. ... Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. |
Baseline and immediate post-stimulation
|
Change from baseline Montgomery Asberg Depression Rating Scale (MADRS)
Time Frame: Baseline and 1 month post-stimulation
|
A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. The MADRS uses a 0 to 6 severity scale, scored following the interview. Scoring/Interpretation: Higher scores indicate increasing depressive symptoms. ... Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression. |
Baseline and 1 month post-stimulation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in functional connectivity from baseline as measured by MR imaging
Time Frame: Baseline and immediate post-stimulation
|
Pre- and post resting state functional connectivity and structural T1-weighted MRI scans to determine the anti-correlated LDLPFC and SCC treatment location.
The identified cluster with the greatest anti-correlation between the LDLPFC and SCC will have been utilized for the targeted aiTBS treatment.
This algorithm will have also been applied to the post-imaging sessions to give measurements of voxel-wise blood flow in this anti-correlation targeted brain ROI.
|
Baseline and immediate post-stimulation
|
Change in functional connectivity from baseline as measured by MR imaging
Time Frame: Baseline and 1 month post-stimulation
|
Pre- and post resting state functional connectivity and structural T1-weighted MRI scans to determine the anti-correlated LDLPFC and SCC treatment location.
The identified cluster with the greatest anti-correlation between the LDLPFC and SCC will have been utilized for the targeted aiTBS treatment.
This algorithm will have also been applied to the post-imaging sessions to give measurements of voxel-wise blood flow in this anti-correlation targeted brain ROI.
|
Baseline and 1 month post-stimulation
|
Change in alcohol craving and consumption measured by Obsessive Compulsive Drinking Scale (OCDS)
Time Frame: Baseline and immediate post-stimulation
|
OCDS is a 14-question self-rate tool to measure obsessive thoughts about alcohol and compulsive use of alcohol.
The minimum obtainable score is 0, while the maximum obtainable score is 56.
Higher scores represent a worse outcome.
|
Baseline and immediate post-stimulation
|
Change in alcohol craving and consumption measured by Obsessive Compulsive Drinking Scale (OCDS)
Time Frame: Baseline and 1 month post-stimulation
|
OCDS is a 14-question self-rate tool to measure obsessive thoughts about alcohol and compulsive use of alcohol.
The minimum obtainable score is 0, while the maximum obtainable score is 56.
Higher scores represent a worse outcome.
|
Baseline and 1 month post-stimulation
|
Change in heart rate variability
Time Frame: At the beginning and end of each stimulation day
|
Heart rate variability will be measured using a NeuroConn device which involves electrodes being placed on the chest to record heart rate.
|
At the beginning and end of each stimulation day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the Delis Kaplan Executive Function System (D-KEFS): Trail Making Test
Time Frame: Baseline and immediate post-stimulation
|
Delis Kaplan Executive Function System (D-KEFS): Trail Making Test Description: The Trail Making Test was used to measure combined visuomotor and executive functioning including sequencing and cognitive switching. The test also provides measures of visual scanning and motor speed. Reference: DELIS DC, KRAMER JH, KAPLAN E, HOLDNACK J. Reliability and validity of the Delis-Kaplan Executive Function System: An update. J Int Neuropsychol Soc. 2004;10(02) |
Baseline and immediate post-stimulation
|
Change from baseline in the Delis Kaplan Executive Function System (D-KEFS): Trail Making Test
Time Frame: Baseline and 1 month post-stimulation
|
Delis Kaplan Executive Function System (D-KEFS): Trail Making Test Description: The Trail Making Test was used to measure combined visuomotor and executive functioning including sequencing and cognitive switching. The test also provides measures of visual scanning and motor speed. Reference: DELIS DC, KRAMER JH, KAPLAN E, HOLDNACK J. Reliability and validity of the Delis-Kaplan Executive Function System: An update. J Int Neuropsychol Soc. 2004;10(02) |
Baseline and 1 month post-stimulation
|
Change from baseline in the Hopkins Verbal Learning Test- Revised (HVLT-R)
Time Frame: Baseline and immediate post-stimulation
|
The Hopkins Verbal Learning Test - Revised (HVLT-R) is given to assess learning and recall of verbal information.
The HVLT-R is a list-learning task with three learning trials, a 20-minute delayed recall, and a recognition paradigm following the delayed recall.
There are six alternate forms that allow for serial evaluation.
|
Baseline and immediate post-stimulation
|
Change from baseline in the Hopkins Verbal Learning Test- Revised (HVLT-R)
Time Frame: Baseline and 1 month post-stimulation
|
The Hopkins Verbal Learning Test - Revised (HVLT-R) is given to assess learning and recall of verbal information.
The HVLT-R is a list-learning task with three learning trials, a 20-minute delayed recall, and a recognition paradigm following the delayed recall.
There are six alternate forms that allow for serial evaluation.
|
Baseline and 1 month post-stimulation
|
Change from baseline in the Brief Visuospatial Memory Test - Revised (BVMT-R)
Time Frame: Baseline and immediate post-stimulation
|
The Brief Visuospatial Memory Test - Revised (BVMT-R) is given to measure learning and memory of visuospatial stimuli.
The BVMT-R is a task that requires the participant to learn an array of simple geometric figures over three learning trials.
There is a delayed recall after 25 minutes and a recognition task following the delay.
There is also a copy task following the memory recall and recognition portions of the test.
There are six alternate forms that allow for serial evaluation.
|
Baseline and immediate post-stimulation
|
Change from baseline in the Brief Visuospatial Memory Test - Revised (BVMT-R)
Time Frame: Baseline and 1-month post-stimulation
|
The Brief Visuospatial Memory Test - Revised (BVMT-R) is given to measure learning and memory of visuospatial stimuli.
The BVMT-R is a task that requires the participant to learn an array of simple geometric figures over three learning trials.
There is a delayed recall after 25 minutes and a recognition task following the delay.
There is also a copy task following the memory recall and recognition portions of the test.
There are six alternate forms that allow for serial evaluation.
|
Baseline and 1-month post-stimulation
|
Change from baseline in the Advanced Clinical Solutions Test of Premorbid Function (TOPF)
Time Frame: Baseline and immediate post-stimulation
|
The Advanced Clinical Solutions Test of Premorbid Function (TOPF) is given to estimate an individual's premorbid cognitive and memory functioning.
Although TOPF is not impervious to the effects of cognitive dysfunction, it appears to be less affected than other measures of intellectual and memory functioning.
The TOPF is based on a reading paradigm, requiring the reading and pronunciation of words that have irregular grapheme-to-phoneme translation.
It does not require comprehension or knowledge of word meaning.
|
Baseline and immediate post-stimulation
|
Change from baseline in the Advanced Clinical Solutions Test of Premorbid Function (TOPF)
Time Frame: Baseline and 1-month post-stimulation
|
The Advanced Clinical Solutions Test of Premorbid Function (TOPF) is given to estimate an individual's premorbid cognitive and memory functioning.
Although TOPF is not impervious to the effects of cognitive dysfunction, it appears to be less affected than other measures of intellectual and memory functioning.
The TOPF is based on a reading paradigm, requiring the reading and pronunciation of words that have irregular grapheme-to-phoneme translation.
It does not require comprehension or knowledge of word meaning.
|
Baseline and 1-month post-stimulation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 47388
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Accelerated theta burst treatment
-
Stanford UniversityActive, not recruitingTreatment Resistant DepressionUnited States
-
Stanford UniversitySchatzberg, Alan, M.D.CompletedTreatment Resistant DepressionUnited States
-
University of California, San DiegoUniversity of Pennsylvania; Milken InstituteActive, not recruiting
-
Stanford UniversityCompletedDepression and SuicideUnited States
-
University of California, San DiegoStanford University; Cornell University; Wellcome Leap OrganizationRecruiting
-
University of California, San DiegoBrain & Behavior Research FoundationRecruitingSuicidal Ideation | Treatment-resistant DepressionUnited States
-
Ontario Shores Centre for Mental Health SciencesSunnybrook Health Sciences CentreRecruitingDepressive Disorder, Treatment-ResistantCanada
-
Brigham and Women's HospitalRecruitingDepression | Mood Disorders | Depressive Disorder, Major | Psychiatric Disorder | Mental DisorderUnited States
-
Central South UniversityRecruitingSchizophrenia | Transcranial Magnetic Stimulation | Metabolic Disturbance | Eating BehaviorChina